Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) Study

The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) recently published an equation for estimated glomerular filtration rate (eGFR) using the same variables (serum creatinine level, age, sex, and race) as the Modification of Diet in Renal Disease (MDRD) Study equation. Although the CKD-EP...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	American journal of kidney diseases Ročník 55; číslo 4; s. 648
Hlavní autoři:	Matsushita, Kunihiro, Selvin, Elizabeth, Bash, Lori D, Astor, Brad C, Coresh, Josef
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.04.2010
Témata:	Cause of Death Chronic Disease Coronary Disease - epidemiology Coronary Disease - etiology Female Glomerular Filtration Rate Humans Kidney Diseases - complications Kidney Diseases - diet therapy Kidney Diseases - epidemiology Kidney Diseases - physiopathology Kidney Failure, Chronic - epidemiology Kidney Failure, Chronic - etiology Male Mathematics Middle Aged Prospective Studies Risk Assessment Stroke - epidemiology Stroke - etiology
ISSN:	1523-6838, 1523-6838
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) recently published an equation for estimated glomerular filtration rate (eGFR) using the same variables (serum creatinine level, age, sex, and race) as the Modification of Diet in Renal Disease (MDRD) Study equation. Although the CKD-EPI equation estimates GFR more precisely compared with the MDRD Study equation, whether this equation improves risk prediction is unknown. Prospective cohort study, the Atherosclerosis Risk in Communities (ARIC) Study. 13,905 middle-aged participants without a history of cardiovascular disease with median follow-up of 16.9 years. eGFR. We compared the association of eGFR in categories (>or=120, 90-119, 60-89, 30-59, and <30 mL/min/1.73 m(2)) using the CKD-EPI and MDRD Study equations with risk of incident end-stage renal disease, all-cause mortality, coronary heart disease, and stroke. The median value for eGFR(CKD-EPI) was higher than that for eGFR(MDRD) (97.6 vs 88.8 mL/min/1.73 m(2); P < 0.001). The CKD-EPI equation reclassified 44.9% (n = 3,079) and 43.5% (n = 151) of participants with eGFR(MDRD) of 60-89 and 30-59 mL/min/1.73 m(2), respectively, upward to a higher eGFR category, but reclassified no one with eGFR(MDRD) of 90-119 or <30 mL/min/1.73 m(2), decreasing the prevalence of CKD stages 3-5 from 2.7% to 1.6%. Participants with eGFR(MDRD) of 30-59 mL/min/1.73 m(2) who were reclassified upward had lower risk compared with those who were not reclassified (end-stage renal disease incidence rate ratio, 0.10 [95% CI, 0.03-0.33]; all-cause mortality, 0.30 [95% CI, 0.19-0.48]; coronary heart disease, 0.36 [95% CI, 0.21-0.61]; and stroke, 0.50 [95% CI, 0.24-1.02]). Similar results were observed for participants with eGFR(MDRD) of 60-89 mL/min/1.73 m(2). More frequent reclassification of younger, female, and white participants explained some of these trends. Net reclassification improvement in participants with eGFR < 120 mL/min/1.73 m(2) was positive for all outcomes (P < 0.001). Limited number of cases with eGFR < 60 mL/min/1.73 m(2) and no measurement of albuminuria. The CKD-EPI equation more appropriately categorized individuals with respect to long-term clinical risk compared with the MDRD Study equation, suggesting improved clinical usefulness in this middle-aged population.
AbstractList	The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) recently published an equation for estimated glomerular filtration rate (eGFR) using the same variables (serum creatinine level, age, sex, and race) as the Modification of Diet in Renal Disease (MDRD) Study equation. Although the CKD-EPI equation estimates GFR more precisely compared with the MDRD Study equation, whether this equation improves risk prediction is unknown. Prospective cohort study, the Atherosclerosis Risk in Communities (ARIC) Study. 13,905 middle-aged participants without a history of cardiovascular disease with median follow-up of 16.9 years. eGFR. We compared the association of eGFR in categories (>or=120, 90-119, 60-89, 30-59, and <30 mL/min/1.73 m(2)) using the CKD-EPI and MDRD Study equations with risk of incident end-stage renal disease, all-cause mortality, coronary heart disease, and stroke. The median value for eGFR(CKD-EPI) was higher than that for eGFR(MDRD) (97.6 vs 88.8 mL/min/1.73 m(2); P < 0.001). The CKD-EPI equation reclassified 44.9% (n = 3,079) and 43.5% (n = 151) of participants with eGFR(MDRD) of 60-89 and 30-59 mL/min/1.73 m(2), respectively, upward to a higher eGFR category, but reclassified no one with eGFR(MDRD) of 90-119 or <30 mL/min/1.73 m(2), decreasing the prevalence of CKD stages 3-5 from 2.7% to 1.6%. Participants with eGFR(MDRD) of 30-59 mL/min/1.73 m(2) who were reclassified upward had lower risk compared with those who were not reclassified (end-stage renal disease incidence rate ratio, 0.10 [95% CI, 0.03-0.33]; all-cause mortality, 0.30 [95% CI, 0.19-0.48]; coronary heart disease, 0.36 [95% CI, 0.21-0.61]; and stroke, 0.50 [95% CI, 0.24-1.02]). Similar results were observed for participants with eGFR(MDRD) of 60-89 mL/min/1.73 m(2). More frequent reclassification of younger, female, and white participants explained some of these trends. Net reclassification improvement in participants with eGFR < 120 mL/min/1.73 m(2) was positive for all outcomes (P < 0.001). Limited number of cases with eGFR < 60 mL/min/1.73 m(2) and no measurement of albuminuria. The CKD-EPI equation more appropriately categorized individuals with respect to long-term clinical risk compared with the MDRD Study equation, suggesting improved clinical usefulness in this middle-aged population. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) recently published an equation for estimated glomerular filtration rate (eGFR) using the same variables (serum creatinine level, age, sex, and race) as the Modification of Diet in Renal Disease (MDRD) Study equation. Although the CKD-EPI equation estimates GFR more precisely compared with the MDRD Study equation, whether this equation improves risk prediction is unknown.BACKGROUNDThe Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) recently published an equation for estimated glomerular filtration rate (eGFR) using the same variables (serum creatinine level, age, sex, and race) as the Modification of Diet in Renal Disease (MDRD) Study equation. Although the CKD-EPI equation estimates GFR more precisely compared with the MDRD Study equation, whether this equation improves risk prediction is unknown.Prospective cohort study, the Atherosclerosis Risk in Communities (ARIC) Study.STUDY DESIGNProspective cohort study, the Atherosclerosis Risk in Communities (ARIC) Study.13,905 middle-aged participants without a history of cardiovascular disease with median follow-up of 16.9 years.SETTING & PARTICIPANTS13,905 middle-aged participants without a history of cardiovascular disease with median follow-up of 16.9 years.eGFR.PREDICTOReGFR.We compared the association of eGFR in categories (>or=120, 90-119, 60-89, 30-59, and <30 mL/min/1.73 m(2)) using the CKD-EPI and MDRD Study equations with risk of incident end-stage renal disease, all-cause mortality, coronary heart disease, and stroke.OUTCOMES & MEASUREMENTSWe compared the association of eGFR in categories (>or=120, 90-119, 60-89, 30-59, and <30 mL/min/1.73 m(2)) using the CKD-EPI and MDRD Study equations with risk of incident end-stage renal disease, all-cause mortality, coronary heart disease, and stroke.The median value for eGFR(CKD-EPI) was higher than that for eGFR(MDRD) (97.6 vs 88.8 mL/min/1.73 m(2); P < 0.001). The CKD-EPI equation reclassified 44.9% (n = 3,079) and 43.5% (n = 151) of participants with eGFR(MDRD) of 60-89 and 30-59 mL/min/1.73 m(2), respectively, upward to a higher eGFR category, but reclassified no one with eGFR(MDRD) of 90-119 or <30 mL/min/1.73 m(2), decreasing the prevalence of CKD stages 3-5 from 2.7% to 1.6%. Participants with eGFR(MDRD) of 30-59 mL/min/1.73 m(2) who were reclassified upward had lower risk compared with those who were not reclassified (end-stage renal disease incidence rate ratio, 0.10 [95% CI, 0.03-0.33]; all-cause mortality, 0.30 [95% CI, 0.19-0.48]; coronary heart disease, 0.36 [95% CI, 0.21-0.61]; and stroke, 0.50 [95% CI, 0.24-1.02]). Similar results were observed for participants with eGFR(MDRD) of 60-89 mL/min/1.73 m(2). More frequent reclassification of younger, female, and white participants explained some of these trends. Net reclassification improvement in participants with eGFR < 120 mL/min/1.73 m(2) was positive for all outcomes (P < 0.001).RESULTSThe median value for eGFR(CKD-EPI) was higher than that for eGFR(MDRD) (97.6 vs 88.8 mL/min/1.73 m(2); P < 0.001). The CKD-EPI equation reclassified 44.9% (n = 3,079) and 43.5% (n = 151) of participants with eGFR(MDRD) of 60-89 and 30-59 mL/min/1.73 m(2), respectively, upward to a higher eGFR category, but reclassified no one with eGFR(MDRD) of 90-119 or <30 mL/min/1.73 m(2), decreasing the prevalence of CKD stages 3-5 from 2.7% to 1.6%. Participants with eGFR(MDRD) of 30-59 mL/min/1.73 m(2) who were reclassified upward had lower risk compared with those who were not reclassified (end-stage renal disease incidence rate ratio, 0.10 [95% CI, 0.03-0.33]; all-cause mortality, 0.30 [95% CI, 0.19-0.48]; coronary heart disease, 0.36 [95% CI, 0.21-0.61]; and stroke, 0.50 [95% CI, 0.24-1.02]). Similar results were observed for participants with eGFR(MDRD) of 60-89 mL/min/1.73 m(2). More frequent reclassification of younger, female, and white participants explained some of these trends. Net reclassification improvement in participants with eGFR < 120 mL/min/1.73 m(2) was positive for all outcomes (P < 0.001).Limited number of cases with eGFR < 60 mL/min/1.73 m(2) and no measurement of albuminuria.LIMITATIONSLimited number of cases with eGFR < 60 mL/min/1.73 m(2) and no measurement of albuminuria.The CKD-EPI equation more appropriately categorized individuals with respect to long-term clinical risk compared with the MDRD Study equation, suggesting improved clinical usefulness in this middle-aged population.CONCLUSIONSThe CKD-EPI equation more appropriately categorized individuals with respect to long-term clinical risk compared with the MDRD Study equation, suggesting improved clinical usefulness in this middle-aged population.
Author	Coresh, Josef Bash, Lori D Astor, Brad C Selvin, Elizabeth Matsushita, Kunihiro
Author_xml	– sequence: 1 givenname: Kunihiro surname: Matsushita fullname: Matsushita, Kunihiro email: kmatsush@jhsph.edu organization: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Welch Center for Prevention, Epidemiology, and Clinical Research, Baltimore, MD 21287, USA. kmatsush@jhsph.edu – sequence: 2 givenname: Elizabeth surname: Selvin fullname: Selvin, Elizabeth – sequence: 3 givenname: Lori D surname: Bash fullname: Bash, Lori D – sequence: 4 givenname: Brad C surname: Astor fullname: Astor, Brad C – sequence: 5 givenname: Josef surname: Coresh fullname: Coresh, Josef
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/20189275$$D View this record in MEDLINE/PubMed
BookMark	eNpNkMtOwzAQRS0E4v0DLJB3lEWCH7GTsqvSAhUgUIF15foBbpM4jRNV_Tc-DtOCYDMzmjm6M3OPwG7lKg3AGUYxRoxezWMxX6iYINSPMYkR5jvgEDNCI57RbPdffQCOvJ-jAFLO98EBQTjrk5Qdgs-J9Qtoy7qwUrTWVR46A9sPDSu9gvn9EI5qq3RpXeHe1zB3RSFmrtmgsBfm0eh5fAn1stu2pCtr0WgFV7b92Og8DidD-NJ2av1HGddA7VtbijagtzeT6w06CKFxXhbf0Xq4va0KW8uyq2xrtYe9wWScX24FT8CeEYXXpz_5GLzdjF7zu-jh6XacDx4iyRLeRjyhJhHcSJRobNKUSTJjXErGqTLBEiGw0llCOJOppoJSNjMIK04MTlTCNTkGF1vdunHLLhw-La2XOlhRadf5aUppFowlWSDPf8huVmo1rZvwY7Oe_hpOvgDnxIbf
CitedBy_id	crossref_primary_10_1371_journal_pone_0116403 crossref_primary_10_1016_j_ijcard_2012_07_011 crossref_primary_10_1177_0003319713491134 crossref_primary_10_5334_gh_780 crossref_primary_10_1016_j_atherosclerosis_2011_04_035 crossref_primary_10_1186_1471_2369_13_4 crossref_primary_10_1038_ki_2014_331 crossref_primary_10_1056_NEJMoa1214234 crossref_primary_10_2215_CJN_04130412 crossref_primary_10_1136_jech_2015_205834 crossref_primary_10_1016_j_rhum_2017_07_001 crossref_primary_10_1136_bmjdrc_2015_000154 crossref_primary_10_1016_j_ejim_2020_04_044 crossref_primary_10_2215_CJN_07370714 crossref_primary_10_1136_bmjopen_2020_048542 crossref_primary_10_1097_HJH_0000000000000924 crossref_primary_10_1016_j_ejvs_2017_01_014 crossref_primary_10_5812_ijem_101977 crossref_primary_10_1016_j_medcle_2013_09_001 crossref_primary_10_1093_qjmed_hct043 crossref_primary_10_1089_end_2012_0244 crossref_primary_10_1016_S0140_6736_20_30045_3 crossref_primary_10_2337_dc12_0259 crossref_primary_10_1093_bja_aeu134 crossref_primary_10_1016_j_envpol_2019_113457 crossref_primary_10_1186_s12882_024_03663_2 crossref_primary_10_1002_jcla_21688 crossref_primary_10_1038_s41598_021_91162_x crossref_primary_10_1097_HJH_0000000000001921 crossref_primary_10_1159_000468531 crossref_primary_10_1177_0003319718780772 crossref_primary_10_1016_j_jacc_2021_04_035 crossref_primary_10_1097_MNH_0b013e32834ba210 crossref_primary_10_5694_mja11_11329 crossref_primary_10_1007_s40620_018_0496_0 crossref_primary_10_1097_MD_0000000000011580 crossref_primary_10_1093_ndt_gfr003 crossref_primary_10_1007_s11255_018_1811_3 crossref_primary_10_1681_ASN_2014010115 crossref_primary_10_1016_j_bone_2021_115869 crossref_primary_10_1007_s11906_015_0581_x crossref_primary_10_1089_heq_2020_0072 crossref_primary_10_1111_nep_12663 crossref_primary_10_1016_j_jvs_2014_03_282 crossref_primary_10_1053_j_ajkd_2024_11_011 crossref_primary_10_1038_s41598_019_42809_3 crossref_primary_10_1097_TP_0000000000000151 crossref_primary_10_1111_nep_12660 crossref_primary_10_1097_HJH_0b013e3283525715 crossref_primary_10_1111_dme_12859 crossref_primary_10_1177_1526602815605311 crossref_primary_10_1016_j_jacc_2013_04_093 crossref_primary_10_1136_bmjopen_2011_000308 crossref_primary_10_1186_s13195_020_00729_9 crossref_primary_10_1016_j_ijcard_2013_10_076 crossref_primary_10_1161_JAHA_116_003917 crossref_primary_10_1177_0091270011420260 crossref_primary_10_1177_2047487316676132 crossref_primary_10_1093_eurjpc_zwad148 crossref_primary_10_29089_2020_20_00098 crossref_primary_10_1016_j_amjcard_2013_03_010 crossref_primary_10_1517_14656566_2010_513972 crossref_primary_10_3310_PYFT6977 crossref_primary_10_1016_j_soard_2021_03_006 crossref_primary_10_1111_jgs_13459 crossref_primary_10_1371_journal_pone_0271197 crossref_primary_10_1371_journal_pone_0228842 crossref_primary_10_1016_j_jacadv_2024_101542 crossref_primary_10_1002_joa3_12306 crossref_primary_10_1136_bmjopen_2019_031550 crossref_primary_10_4250_jcvi_2021_0110 crossref_primary_10_1136_bmjopen_2021_049017 crossref_primary_10_2165_11588280_000000000_00000 crossref_primary_10_1097_MAJ_0000000000000446 crossref_primary_10_1371_journal_pone_0143434 crossref_primary_10_1016_j_jbspin_2015_10_006 crossref_primary_10_1136_jech_2012_202307 crossref_primary_10_1007_s11255_011_9923_z crossref_primary_10_1016_j_thromres_2013_06_025 crossref_primary_10_1093_ndt_gfr657 crossref_primary_10_1053_j_ajkd_2014_10_013 crossref_primary_10_1016_j_ijcard_2013_08_142 crossref_primary_10_2215_CJN_04960512 crossref_primary_10_1007_s40620_014_0087_7 crossref_primary_10_1038_ki_2010_462 crossref_primary_10_1038_s41598_017_17397_9 crossref_primary_10_1016_j_jacep_2021_06_009 crossref_primary_10_1016_j_nephro_2012_03_002 crossref_primary_10_5812_jjcdc_138367 crossref_primary_10_1371_journal_pone_0212590 crossref_primary_10_1186_1471_2369_13_58 crossref_primary_10_1186_1471_2369_13_133 crossref_primary_10_1038_s41598_020_68010_5 crossref_primary_10_1093_ndt_gfr323 crossref_primary_10_1002_oby_20497 crossref_primary_10_1038_hr_2011_1 crossref_primary_10_1111_j_1755_6686_2012_00274_x crossref_primary_10_1515_cclm_2013_0223 crossref_primary_10_2215_CJN_03110410 crossref_primary_10_1111_ijcp_12516 crossref_primary_10_1186_1471_2369_13_42 crossref_primary_10_1177_0003319713502847 crossref_primary_10_1016_j_wneu_2018_12_018 crossref_primary_10_1053_j_ajkd_2013_12_006 crossref_primary_10_1007_s11255_012_0188_y crossref_primary_10_1007_s11606_020_06380_2 crossref_primary_10_1016_j_amjmed_2015_03_024 crossref_primary_10_3109_0886022X_2011_605533 crossref_primary_10_1097_MD_0000000000002682 crossref_primary_10_1016_j_ahj_2011_06_006 crossref_primary_10_1016_j_mayocp_2020_03_029 crossref_primary_10_1681_ASN_2010111189 crossref_primary_10_1667_RR13834_1 crossref_primary_10_1016_j_jacc_2021_04_094 crossref_primary_10_1016_j_repce_2017_05_010 crossref_primary_10_1007_s00392_014_0687_1 crossref_primary_10_1016_j_ahj_2013_06_005 crossref_primary_10_1053_j_ajkd_2010_11_007 crossref_primary_10_1016_j_ahj_2013_06_006 crossref_primary_10_1186_s13195_024_01401_2 crossref_primary_10_1053_j_ajkd_2010_11_008 crossref_primary_10_1007_s40200_018_00382_y crossref_primary_10_1016_j_eclinm_2025_103102 crossref_primary_10_1093_ajh_hpu160 crossref_primary_10_1093_ndt_gft006 crossref_primary_10_1016_j_clinthera_2011_05_004 crossref_primary_10_1186_s12882_015_0202_6 crossref_primary_10_6061_clinics_2013_07_28 crossref_primary_10_1038_nrneph_2013_143 crossref_primary_10_1016_j_biochi_2018_06_009 crossref_primary_10_1155_2013_848963 crossref_primary_10_1007_s11255_012_0325_7 crossref_primary_10_3390_nu14132695 crossref_primary_10_1016_j_cqn_2012_09_004 crossref_primary_10_1016_j_ijcard_2013_07_021 crossref_primary_10_1177_0003319715627734 crossref_primary_10_1007_s10157_018_1626_7 crossref_primary_10_2215_CJN_03460412 crossref_primary_10_1093_eurheartj_eht328 crossref_primary_10_1016_j_jvs_2013_03_036 crossref_primary_10_1093_ndt_gfaa293 crossref_primary_10_1186_1471_2369_14_132 crossref_primary_10_2215_CJN_12651214 crossref_primary_10_1016_j_artere_2020_05_005 crossref_primary_10_1128_aac_00462_25 crossref_primary_10_1007_s10620_015_3918_z crossref_primary_10_1371_journal_pone_0239871 crossref_primary_10_3109_0886022X_2011_618922 crossref_primary_10_1093_qjmed_hcr122 crossref_primary_10_1186_s12967_020_02686_1 crossref_primary_10_1016_S0140_6736_17_30788_2 crossref_primary_10_1111_nep_12283 crossref_primary_10_2147_CIA_S250535 crossref_primary_10_1111_j_1440_1797_2011_01455_x crossref_primary_10_1016_j_clinbiochem_2022_10_011 crossref_primary_10_1016_j_carrev_2022_12_011 crossref_primary_10_1016_j_jstrokecerebrovasdis_2010_08_011 crossref_primary_10_1016_j_ultrasmedbio_2018_07_001 crossref_primary_10_3389_fmed_2022_817833 crossref_primary_10_1080_00365513_2017_1292362 crossref_primary_10_1161_JAHA_119_015012 crossref_primary_10_1007_s11255_012_0131_2 crossref_primary_10_1097_QAI_0b013e31823a6124 crossref_primary_10_1053_j_ajkd_2012_03_016 crossref_primary_10_3390_ijerph191711051 crossref_primary_10_1093_ndt_gfs047 crossref_primary_10_1093_eurjhf_hft022 crossref_primary_10_1111_j_1464_5491_2010_03161_x crossref_primary_10_1111_jocs_14834 crossref_primary_10_1001_jamanetworkopen_2024_0351 crossref_primary_10_1007_s10157_017_1463_0 crossref_primary_10_1016_j_immbio_2010_12_001 crossref_primary_10_1002_ejhf_14 crossref_primary_10_1089_aid_2011_0243 crossref_primary_10_1111_jch_12254 crossref_primary_10_1080_0886022X_2019_1662440 crossref_primary_10_1186_1471_2369_15_97 crossref_primary_10_1016_j_ancard_2014_04_006 crossref_primary_10_3390_ijms21228706 crossref_primary_10_1007_s40520_017_0739_2 crossref_primary_10_1016_j_atherosclerosis_2016_06_001 crossref_primary_10_1093_ajh_hpv059 crossref_primary_10_1371_journal_pone_0195784 crossref_primary_10_1007_s12011_022_03524_9 crossref_primary_10_1053_j_ajkd_2013_10_002 crossref_primary_10_2217_fvl_14_55 crossref_primary_10_1093_ndt_gft206 crossref_primary_10_1161_CIRCHEARTFAILURE_112_968545 crossref_primary_10_4103_abr_abr_204_23 crossref_primary_10_1002_j_2040_4603_2013_tb00489_x crossref_primary_10_1093_ndt_gfq618 crossref_primary_10_1007_s40620_015_0244_7 crossref_primary_10_1371_journal_pone_0062328 crossref_primary_10_1093_ndt_gfs344 crossref_primary_10_1093_qjmed_hcr077 crossref_primary_10_1016_j_repc_2017_05_009 crossref_primary_10_1007_s11739_015_1260_2 crossref_primary_10_1136_bmjopen_2013_003631 crossref_primary_10_1186_s12882_017_0653_z crossref_primary_10_1177_0003319714532168 crossref_primary_10_1016_j_ypmed_2016_06_004 crossref_primary_10_1053_j_ajkd_2012_06_016 crossref_primary_10_1053_j_ajkd_2012_06_015 crossref_primary_10_1053_j_ajkd_2013_08_008 crossref_primary_10_1016_j_ijcard_2012_10_054 crossref_primary_10_1186_s12879_024_09278_0 crossref_primary_10_22141_2307_1257_14_3_2025_546 crossref_primary_10_1053_j_ajkd_2010_03_026 crossref_primary_10_1016_j_ejim_2012_01_001 crossref_primary_10_1097_MAJ_0b013e3181e59078 crossref_primary_10_1161_JAHA_120_016463 crossref_primary_10_1038_nrneph_2011_153 crossref_primary_10_1371_journal_pone_0078475 crossref_primary_10_1016_S0140_6736_10_60674_5 crossref_primary_10_3109_07853890_2011_580775 crossref_primary_10_1159_000542912 crossref_primary_10_1016_j_rce_2011_08_001 crossref_primary_10_2215_CJN_08340814 crossref_primary_10_1007_s40620_014_0116_6 crossref_primary_10_1590_1806_9282_20221101 crossref_primary_10_1016_j_ijcard_2012_08_025 crossref_primary_10_1289_ehp_1510269 crossref_primary_10_1053_j_ajkd_2010_02_337 crossref_primary_10_1371_journal_pone_0093748 crossref_primary_10_1161_HYPERTENSIONAHA_118_12094 crossref_primary_10_2215_CJN_03130411 crossref_primary_10_1186_s12967_018_1603_7 crossref_primary_10_1016_j_semnephrol_2011_11_002
ContentType	Journal Article
Copyright	Copyright 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Copyright_xml	– notice: Copyright 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1053/j.ajkd.2009.12.016
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine Mathematics
EISSN	1523-6838
ExternalDocumentID	20189275
Genre	Comparative Study Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: NHLBI NIH HHS grantid: N01-HC-55016 – fundername: NHLBI NIH HHS grantid: N01 HC055016 – fundername: NIDDK NIH HHS grantid: R01DK076770 – fundername: NIDDK NIH HHS grantid: K01DK076595 – fundername: NHLBI NIH HHS grantid: T32HL07024 – fundername: NHLBI NIH HHS grantid: N01 HC055019 – fundername: NHLBI NIH HHS grantid: N01 HC055022 – fundername: NHLBI NIH HHS grantid: N01-HC-55022 – fundername: NHLBI NIH HHS grantid: N01-HC-55018 – fundername: NHLBI NIH HHS grantid: N01 HC055018
GroupedDBID	--- --K .1- .55 .FO .GJ 0R~ 1B1 1P~ 23M 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 AAEDT AAEDW AALRI AAQFI AAQQT AAQXK AAWTL AAXUO AAYOK AAYWO ABCQX ABFRF ABJNI ABLJU ABMAC ABOCM ABWVN ACGFO ACGFS ACRPL ADBBV ADMUD ADNMO ADVLN AEFWE AENEX AEVXI AFCTW AFFNX AFJKZ AFRHN AFTJW AGCQF AGHFR AGQPQ AITUG AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP ASPBG AVWKF AZFZN BELOY CAG CGR COF CS3 CUY CVF EBS ECM EFJIC EIF EJD EX3 F5P FDB FEDTE FGOYB GBLVA HVGLF HZ~ J5H K-O KOM L7B M41 MO0 N4W NPM O9- OE- P2P PC. PI~ R2- ROL SEL SES SJN SSZ TWZ UNMZH WOW X7M XH2 YCW Z5R ZGI ZXP 7X8 AAFWJ ACVFH ADCNI EFKBS
ID	FETCH-LOGICAL-c546t-643f4a6fc04e1f775c2b56cc563df093aa1de84265c7e3a335bf01d62f14d46e2
IEDL.DBID	7X8
ISICitedReferencesCount	258
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000276054500009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1523-6838
IngestDate	Wed Oct 01 14:44:49 EDT 2025 Sat May 31 02:10:31 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	4
Language	English
License	Copyright 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c546t-643f4a6fc04e1f775c2b56cc563df093aa1de84265c7e3a335bf01d62f14d46e2
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
PMID	20189275
PQID	733836628
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_733836628 pubmed_primary_20189275
PublicationCentury	2000
PublicationDate	2010-04-01
PublicationDateYYYYMMDD	2010-04-01
PublicationDate_xml	– month: 04 year: 2010 text: 2010-04-01 day: 01
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	American journal of kidney diseases
PublicationTitleAlternate	Am J Kidney Dis
PublicationYear	2010
References	20338463 - Am J Kidney Dis. 2010 Apr;55(4):622-7. doi: 10.1053/j.ajkd.2010.02.337.
References_xml	– reference: 20338463 - Am J Kidney Dis. 2010 Apr;55(4):622-7. doi: 10.1053/j.ajkd.2010.02.337.
SSID	ssj0009366
Score	2.4655309
Snippet	The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) recently published an equation for estimated glomerular filtration rate (eGFR) using the same...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	648
SubjectTerms	Cause of Death Chronic Disease Coronary Disease - epidemiology Coronary Disease - etiology Female Glomerular Filtration Rate Humans Kidney Diseases - complications Kidney Diseases - diet therapy Kidney Diseases - epidemiology Kidney Diseases - physiopathology Kidney Failure, Chronic - epidemiology Kidney Failure, Chronic - etiology Male Mathematics Middle Aged Prospective Studies Risk Assessment Stroke - epidemiology Stroke - etiology
Title	Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) Study
URI	https://www.ncbi.nlm.nih.gov/pubmed/20189275 https://www.proquest.com/docview/733836628
Volume	55
WOSCitedRecordID	wos000276054500009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LaxsxEBZJXUIuTV9J3bRlDj3YBzXe1eqxvQTjR2qKjTEt-GZkPcAJ7NrdtJD_lh-X0e469qXkEBZ02VkhmFnpk-bTN4R8dU4nPGUplU5o3KAoQ5d-aamzTCPCtzrWSVlsQk4maj5PpzU3p6hplds5sZyobW7CGfmFDHspIWJ1ud7QUDQqJFfrChqHpMEQyYSglvOdWHjKylQlrlCMCsVUfWcGw-7i-pu-vrGVXGU4DYzE_xFmudIMT545xtfkVQ0xoVvFxBty4LK35GhcJ9HfkfvZqriB1R6VHHIPCAQBITb0fvZhsCsbewe9_UiBFr6ng-moDW5TqYTDlsYO4Uy37Gfcn_UhMBTvdlYIjiEoeiBCRtOr4ex7adoNADQvcKDYrgqoxpZBfXElyL1Cqzsb9dpVh-_J7-HgV-8HrYs4UMMTcUsR8fhEC286iYu8lNzESy6M4YJZjy7SOrJOIU7gRjqmGeNL34msiH2U2ES4-JS8yPLMfSCA4FAh4EqUC7JrWuDDnVepjSQLSnNNAlu3LPAnCZkPnbn8b7F4dEyTnFWuXawrMY8FAiCVxpJ_fPrjc3JccQcCb-cTaXicINxn8tL8u10Vf76UwYftZDp-AHSO5UY
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risk+implications+of+the+new+CKD+Epidemiology+Collaboration+%28CKD-EPI%29+equation+compared+with+the+MDRD+Study+equation+for+estimated+GFR%3A+the+Atherosclerosis+Risk+in+Communities+%28ARIC%29+Study&rft.jtitle=American+journal+of+kidney+diseases&rft.au=Matsushita%2C+Kunihiro&rft.au=Selvin%2C+Elizabeth&rft.au=Bash%2C+Lori+D&rft.au=Astor%2C+Brad+C&rft.date=2010-04-01&rft.eissn=1523-6838&rft.volume=55&rft.issue=4&rft.spage=648&rft_id=info:doi/10.1053%2Fj.ajkd.2009.12.016&rft_id=info%3Apmid%2F20189275&rft_id=info%3Apmid%2F20189275&rft.externalDocID=20189275
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1523-6838&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1523-6838&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1523-6838&client=summon